血清HE4和CA125在卵巢癌早期筛查中的临床价值  

Clinical value of serum HE4 and CA125 in early screening of ovarian cancer

作　　者：张翠兰[1] 苏亦平[2] ZHANG Cui-Lan;SU Yi-Ping(Department of Gynecology and Obstetrics, the Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu 211100, China)

机构地区：[1]南京医科大学附属南京市江宁医院妇产科,江苏南京211100 [2]南京医科大学附属南京市妇幼保健院妇科,江苏南京211000

出　　处：《中国妇幼保健》2017年第24期6121-6123,共3页Maternal and Child Health Care of China

摘　　要：目的探讨血清HE4和CA125在卵巢癌早期筛查中的临床价值。方法选取2013年10月-2017年3月在该院确诊为卵巢癌的患者50例为卵巢癌组,选取同期在该院进行妇科检查时发现的卵巢良性疾病患者50例为良性组,妇科门诊健康体检50例为对照组。采用免疫化学发光法和酶联免疫吸附法检测所有研究对象血清HE4、CA125水平,分析其对卵巢癌早期诊断的价值。结果卵巢癌组血清HE4、CA125水平均高于良性组和对照组,良性组高于对照组,差异有统计学意义(P<0.05);联合检测血清HE4、CA125水平对卵巢癌诊断的敏感性、特异性及诊断符合率均高于单一检测,差异有统计学意义(P<0.05);Ⅲ-Ⅳ期患者血清HE4、CA125水平均高于Ⅰ-Ⅱ期,差异有统计学意义(P<0.05)。结论 HE4、CA125在卵巢癌患者血清中呈高水平状态,联合检测其血清水平有利于卵巢癌的早期诊断,可为临床个性化防治提供科学依据。Objective To explore the clinical value of serum human epididymis protein 4 （HE4） and CA125 in early screening of ovarian cancer.Methods From October 2013 to March 2017,50 patients diagnosed as ovarian cancer definitely in the hospital were selected as ovarian cancer group,50 patients diagnosed as ovarian benign diseases during gynecological examination in the hospital were selected as benign group,50 women receiving healthy physical examination in Gynecological Clinic of the hospital were selected as control group.Immunochemiluminometric assay and ELISA were used to detect the levels of serum HE4 and CA125.The value of HE4 and CA125 in early diagnosis of ovarian cancer was analyzed.Results The levels of serum HE4 and CA125 in ovarian cancer group were statistically significantly higher than those in benign group and control group,the levels of serum HE4 and CA125 in benign group were statistically significantly higher than those in control group （P〈0.05）.The sensitivity,specificity,and diagnostic coincidence rate of combined detection of serum HE4 and CA125 were statistically significantly higher than those of single detection of serum HE4 and CA125 （P〈0.05）.The levels of serum HE4 and CA125 in ovarian cancer patients of stage Ⅲ-Ⅲ were statistically significantly higher than those in ovarian cancer patients of stage Ⅰ-Ⅱ （P〈0.05）.Conclusion The levels of serum HE4 and CA125 in patients with ovarian cancer are high,combined detection of serum HE4 and CA125 is helpful for early diagnosis of ovarian cancer,which can provide a scientific basis for clinical personalized prevention and treatment of ovarian cancer.

关 键 词：HE4 CA125 卵巢癌 早期筛查 

分 类 号：R737.31[医药卫生—肿瘤]